A 24-week Off Drug Extension Parallel Group Study Assessing the Durability of Effect on Skeletal Muscle Strength and Function Following a 6-month Double-blind Placebo-controlled Study Evaluating Bimagrumab in Older Adults With Sarcopenia

Trial Profile

A 24-week Off Drug Extension Parallel Group Study Assessing the Durability of Effect on Skeletal Muscle Strength and Function Following a 6-month Double-blind Placebo-controlled Study Evaluating Bimagrumab in Older Adults With Sarcopenia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Bimagrumab (Primary)
  • Indications Muscular atrophy
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 23 Jul 2017 Planned number of patients changed from 125 to 200.
    • 23 Jul 2017 Planned End Date changed from 21 Aug 2019 to 19 Aug 2019.
    • 23 Jul 2017 Planned primary completion date changed from 20 Sep 2018 to 18 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top